The applied WTP threshold in the technology appraisals that focused on first line treatment of EGFR-, ALK- or ROS1-positive NSCLC was £20,000 - £30,000 per QALY overall (Table 1, Appendix B). Here, ROS1 is linked to non-small cell lung carcinoma.